Roy W. Beck
Auto-generated profile, based on publicly available information

Roy W. Beck

Jaeb Center for Health Research, Tampa, Florida, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
TBTadej Battelino
Tadej Battelino
TDThomas Danne
Thomas Danne
RBRichard M. Bergenstal
Richard M. Bergenstal
SAStephanie A. Amiel
Stephanie A. Amiel
RBRoy Beck
Roy Beck
MPMoshe Phillip
Moshe Phillip
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

10 November 2017 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
TDThomas Danne
Thomas Danne
RNRevital Nimri
Revital Nimri
TBTadej Battelino
Tadej Battelino
RBRichard M. Bergenstal
Richard M. Bergenstal
KCKelly L. Close
Kelly L. Close
MPMoshe Phillip
Moshe Phillip
Measurement of glycated hemoglobin (HbA1c) has been the traditional method for assessing glycemic control. However, it does not reflect intra- and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.

24 January 2017 in JAMA
Verified
Journal Article
Open access
PDF file
RBRoy W. Beck
Roy W. Beck
TRTonya Riddlesworth
Tonya Riddlesworth
KRKatrina Ruedy
Katrina Ruedy
AAAndrew Ahmann
Andrew Ahmann
RBRichard Bergenstal
Richard Bergenstal
FGfor the DIAMOND Study Group
for the DIAMOND Study Group
Quiz Ref ID Only approximately 30% of individuals with type 1 diabetes meet the American Diabetes Association goal of hemoglobin A1c (HbA1c) level of 7.5% (58 mmol/mol) for children (<18 years) and 7.0% (53 mmol/mol) for adults (≥18 years),1 indicating the need for better approaches to diabetes management. Continuous glucose monitoring (CGM) with glucose measurements as often as every 5 minutes, plus low and high glucose level alerts and glucose trend information, has the capability of better informing diabetes management decisions than blood glucose meter testing performed several times a day. Randomized clinical trials have demonstrated the benefit of CGM in adults with type 1 diabetes, but not consistently in children, to improve glycemic control as measured by HbA1c level and to reduce hypoglycemia.2-6 These previous trials have either completely or predominantly included insulin pump users,2,4,5 although the majority of adults with type 1 diabetes deliver insulin via injections.7,8

23 October 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
RBRoy W. Beck
Roy W. Beck
RBRichard M. Bergenstal
Richard M. Bergenstal
TRTonya D. Riddlesworth
Tonya D. Riddlesworth
CKCraig Kollman
Craig Kollman
ZLZhaomian Li
Zhaomian Li
KCKelly L. Close
Kelly L. Close
OBJECTIVE This study evaluated the association of time in range (TIR) of 70–180 mg/dL (3.9–10 mmol/L) with the development or progression of retinopathy and development of microalbuminuria using the Diabetes Control and Complications (DCCT) data set in order to validate the use of TIR as an outcome measure for clinical trials. RESEARCH DESIGN AND METHODS In the DCCT, blood glucose concentrations were measured at a central laboratory from seven fingerstick samples (seven-point testing: pre- and 90-min postmeals and at bedtime) collected during 1 day every 3 months. Retinopathy progression was assessed every 6 months and urinary microalbuminuria development every 12 months. Proportional hazards models were used to assess the association of TIR and other glycemic metrics, computed from the seven-point fingerstick data, with the rate of development of microvascular complications. RESULTS Mean TIR of seven-point profiles for the 1,440 participants was 41 ± 16%. The hazard rate of development of retinopathy progression was increased by 64% (95% CI 51–78), and development of the microalbuminuria outcome was increased by 40% (95% CI 25–56) for each 10 percentage points lower TIR (P < 0.001 for each). Results were similar for mean glucose and hyperglycemia metrics. CONCLUSIONS Based on these results, a compelling case can be made that TIR is strongly associated with the risk of microvascular complications and should be an acceptable end point for clinical trials. Although hemoglobin A1c remains a valuable outcome metric in clinical trials, TIR and other glycemic metrics—especially when measured with continuous glucose monitoring—add value as outcome measures in many studies.

17 September 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
RBRichard M. Bergenstal
Richard M. Bergenstal
RBRoy W. Beck
Roy W. Beck
KCKelly L. Close
Kelly L. Close
GGGeorge Grunberger
George Grunberger
DSDavid B Sacks
David B Sacks
WCWilliam T. Cefalu
William T. Cefalu
While A1C is well established as an important risk marker for diabetes complications, with the increasing use of continuous glucose monitoring (CGM) to help facilitate safe and effective diabetes management, it is important to understand how CGM metrics, such as mean glucose, and A1C correlate. Estimated A1C (eA1C) is a measure converting the mean glucose from CGM or self-monitored blood glucose readings, using a formula derived from glucose readings from a population of individuals, into an estimate of a simultaneously measured laboratory A1C. Many patients and clinicians find the eA1C to be a helpful educational tool, but others are often confused or even frustrated if the eA1C and laboratory-measured A1C do not agree. In the U.S., the Food and Drug Administration determined that the nomenclature of eA1C needed to change. This led the authors to work toward a multipart solution to facilitate the retention of such a metric, which includes renaming the eA1C the glucose management indicator (GMI) and generating a new formula for converting CGM-derived mean glucose to GMI based on recent clinical trials using the most accurate CGM systems available. The final aspect of ensuring a smooth transition from the old eA1C to the new GMI is providing new CGM analyses and explanations to further understand how to interpret GMI and use it most effectively in clinical practice. This Perspective will address why a new name for eA1C was needed, why GMI was selected as the new name, how GMI is calculated, and how to understand and explain GMI if one chooses to use GMI as a tool in diabetes education or management.

19 September 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
RBRoy W. Beck
Roy W. Beck
TRTonya D. Riddlesworth
Tonya D. Riddlesworth
KRKatrina Ruedy
Katrina Ruedy
AAAndrew Ahmann
Andrew Ahmann
SHStacie Haller
Stacie Haller
FGfor the DIAMOND Study Group*
for the DIAMOND Study Group*
Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2 diabetes receiving insulin. To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin. Randomized clinical trial. (The protocol also included a type 1 diabetes cohort in a parallel trial and subsequent second trial.) (ClinicalTrials.gov: NCT02282397) 25 endocrinology practices in North America. 158 adults who had had type 2 diabetes for a median of 17 years (interquartile range, 11 to 23 years). Participants were aged 35 to 79 years (mean, 60 years [SD, 10]), were receiving multiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%). Random assignment to CGM (n = 79) or usual care (control group, n = 79). The primary outcome was HbA1c reduction at 24 weeks. Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adjusted difference in mean change, −0.3% [95% CI, −0.5% to 0.0%]; P = 0.022). The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes. The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week. 6-month follow-up. A high percentage of adults who received multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had improved glycemic control. Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support an additional management method that may benefit these patients. Dexcom.